Evaluation of Tumor Budding in Predicting Survival for Gastric Carcinoma Patients in Vietnam

• Published in: Cancer control Vol. 27; no. 1; p. 1073274820968883
• Main Authors: Dao, Tu Van, Nguyen, Chu Van, Nguyen, Quang Tien, Vu, Ha Thi Ngoc, Phung, Huyen Thi, Bui, Oanh Thi, Nguyen, Dung Khac, Luong, Bang Viet, Tran, Thuan Van
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.10.2020; Sage Publications Ltd; SAGE Publishing
• Subjects: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Capecitabine - therapeutic use; Carcinoma; Carcinoma - mortality; Carcinoma - pathology; Carcinoma - therapy; Chemotherapy; Chemotherapy, Adjuvant - methods; Disease-Free Survival; Female; Follow-Up Studies; Gastrectomy; Gastric cancer; Humans; Kaplan-Meier Estimate; Male; Medical prognosis; Middle Aged; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - pathology; Original Research Paper; Oxaloacetates - therapeutic use; Patients; Prognosis; Retrospective Studies; Risk Assessment - methods; Stomach - pathology; Stomach - surgery; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Stomach Neoplasms - therapy; Surgery; Survival; Vietnam - epidemiology; Vietnam; clinical; pathology; gastric cancer; prognosis; tumor budding
• ISSN: 1073-2748; 1526-2359; 1526-2359; 1073-2748
• DOI: 10.1177/1073274820968883

Background: Tumor budding (Bd) has been demonstrated to be a promising prognostic factor in many carcinomas and in gastric cancer. It may represent an optimal additional parameter that is helpful for risk stratification in gastric adenocarcinoma. Hence, the present research was designed to predict the survival outcomes of gastric cancer in Vietnam, applying the tumor budding criteria of the International Tumor Budding Consensus Conference (ITBCC) 2016. Methods: The present study was conducted on 109 gastric cancer patients who underwent surgery but did not receive neo-adjuvant chemotherapy from 2012 to 2015. The patients’ clinicopathological features were recorded. Bd was evaluated according to the 2016 ITBCC criteria and classified as Bd1 (0–4 buds), Bd2 (5–9 buds), and Bd3 (≥10 buds) grades, in addition to being categorized into 2 main Bd groups: low (<10 buds) and high (≥10 buds) Bd. Kaplan–Meier and log-rank models were applied to analyze survival proportions. Results: Of all the patients, 22.9% were classified as Bd1, 31.2% as Bd2, and 45.9% as Bd3 grades. Furthermore, 54.1% patients were categorized into the low and 45.9% into the high Bd groups. Patients with Bd1 and Bd2 grades (the low Bd group) exhibited the best prognosis, with 5-year overall survival (OS) rates of 85.7%, 90.8%, and90.3%, respectively. Patients with Bd3 grade (the high Bd group exhibited the worst prognosis, and none of them lived for 5 years (p < 0.001). Similar to OS rates, disease-free survival (DFS) rates markedly reduced from the Bd1 to Bd3 grade: Bd1, 95.0%; Bd2, 84.7%; and Bd3, 0% (p < 0.001). Conclusion: Patients with different gastric cancer Bd grades exhibited significantly different OS and DFS rates. The present study findings suggest that the ITBCC criteria can be used to stratify Bd for the treatment and prognosis of gastric cancer patients in Vietnam.